The Comparative Effect of Nisin and Thioridazine as Potential Anticancer Agents on Hepatocellular Carcinoma.
Hepatocellular carcinoma
Nisin
Thioridazine
Journal
Reports of biochemistry & molecular biology
ISSN: 2322-3480
Titre abrégé: Rep Biochem Mol Biol
Pays: Iran
ID NLM: 101637937
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma is a major health problem worldwide especially in Egypt. It accounts for the fifth common cancer and the second cause of death among different cancers. This study investigated the efficacy and molecular mechanism of Nisin and/or Thioridazine as anticancer treatment on human liver cancer HepG2 cell line. Nisin and Thioridazine were applied for 24 h on human liver cancer cell line (HepG2). 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was done to assess the cytotoxicity of Nisin and Thioridazine. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used for the assessment of PI3K, AKT, SIRT-1, and NRF2 expression in the treated cell line. The protein level of reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF) was measured in the collected media by ELISA technique. Western blot analysis was done for, tAKT, pAKT, tPI3K, and pPI3K. Cell proliferation results showed that compared with the untreated cancer, Nisin and/or Thioridazine treated groups had decreased cell proliferation (p value< 0.0001). Nisin and/or Thioridazine decreased PI3K/AKT mRNA and protein expression in hepatocellular carcinoma cells (HCC). Also Nisin and/or Thioridazine decreased anti-oxidative SIRT1/NRF2 mRNA expression. ROS level highly increased with Nisin and/or Thioridazine treatment in contrast to VEGF protein level which was highly decreased. These results introduce Nisin and Thioridazine as new therapeutic lines in HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma is a major health problem worldwide especially in Egypt. It accounts for the fifth common cancer and the second cause of death among different cancers. This study investigated the efficacy and molecular mechanism of Nisin and/or Thioridazine as anticancer treatment on human liver cancer HepG2 cell line.
METHODS
METHODS
Nisin and Thioridazine were applied for 24 h on human liver cancer cell line (HepG2). 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was done to assess the cytotoxicity of Nisin and Thioridazine. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used for the assessment of PI3K, AKT, SIRT-1, and NRF2 expression in the treated cell line. The protein level of reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF) was measured in the collected media by ELISA technique. Western blot analysis was done for, tAKT, pAKT, tPI3K, and pPI3K.
RESULTS
RESULTS
Cell proliferation results showed that compared with the untreated cancer, Nisin and/or Thioridazine treated groups had decreased cell proliferation (p value< 0.0001). Nisin and/or Thioridazine decreased PI3K/AKT mRNA and protein expression in hepatocellular carcinoma cells (HCC). Also Nisin and/or Thioridazine decreased anti-oxidative SIRT1/NRF2 mRNA expression. ROS level highly increased with Nisin and/or Thioridazine treatment in contrast to VEGF protein level which was highly decreased.
CONCLUSION
CONCLUSIONS
These results introduce Nisin and Thioridazine as new therapeutic lines in HCC.
Identifiants
pubmed: 33969139
doi: 10.52547/rbmb.9.4.452
pii: rbmb-9-452
pmc: PMC8068446
doi:
Types de publication
Journal Article
Langues
eng
Pagination
452-462Références
Cancer Res. 1990 Sep 1;50(17):5399-405
pubmed: 2386945
Oncotarget. 2019 Mar 12;10(21):2055-2067
pubmed: 31007848
Int J Mol Med. 2016 Apr;37(4):1049-58
pubmed: 26935021
Oncotarget. 2014 Jul 15;5(13):4929-34
pubmed: 24952635
Am J Psychiatry. 1984 Mar;141(3):440-2
pubmed: 6367494
Oncol Rep. 2017 Feb;37(2):1168-1174
pubmed: 28000884
Cancer Med. 2012 Dec;1(3):295-305
pubmed: 23342279
Gynecol Oncol. 2011 Jan;120(1):121-7
pubmed: 21035837
Mol Med Rep. 2015 Sep;12(3):4103-4108
pubmed: 26095429
Biomed Res Int. 2016;2016:6709828
pubmed: 27556038
Oncol Lett. 2017 Dec;14(6):8171-8177
pubmed: 29344260
Oncologist. 2013;18(4):430-8
pubmed: 23576483
Cell Death Dis. 2015 May 07;6:e1753
pubmed: 25950483
Biomed Pharmacother. 2018 Jan;97:833-837
pubmed: 29136758
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
Onco Targets Ther. 2015 Jun 22;8:1543-52
pubmed: 26124671
Anticancer Res. 2016 Nov;36(11):5701-5706
pubmed: 27793891
PLoS One. 2010 Sep 09;5(9):
pubmed: 20844587
Oncol Rep. 2006 Jan;15(1):107-12
pubmed: 16328041
Cell Mol Life Sci. 2008 Feb;65(3):455-76
pubmed: 17965835
J Clin Oncol. 2014 Jan 10;32(2):129-60
pubmed: 24327669
Oncol Lett. 2017 Mar;13(3):1563-1568
pubmed: 28454291
Hum Antibodies. 2019;27(2):105-110
pubmed: 30594921
Oncol Rep. 2014 May;31(5):2107-14
pubmed: 24604290
J Appl Microbiol. 2016 Jun;120(6):1449-65
pubmed: 26678028
Exp Mol Med. 2016 Nov 4;48(11):e269
pubmed: 27811934
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Apoptosis. 2012 Sep;17(9):989-97
pubmed: 22460505
Int J Mol Sci. 2013 Feb 11;14(2):3834-59
pubmed: 23434668
Tumour Biol. 2015 Nov;36(11):8301-8
pubmed: 26002579
Singapore Med J. 2003 Aug;44(8):391-6
pubmed: 14700417
J Proteomics. 2015 Apr 24;119:230-7
pubmed: 25724729
World J Hepatol. 2013 Mar 27;5(3):97-103
pubmed: 23556040
Microvasc Res. 2012 Nov;84(3):227-34
pubmed: 23022044
Arch Med Sci. 2018 Apr;14(3):617-624
pubmed: 29765450
Am J Transl Res. 2016 Jun 15;8(6):2767-75
pubmed: 27398159
Mol Oncol. 2015 Aug;9(7):1259-73
pubmed: 25841766
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Rep Biochem Mol Biol. 2020 Jul;9(2):230-240
pubmed: 33178874
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2217-2222
pubmed: 30139228
PLoS One. 2013 May 17;8(5):e64518
pubmed: 23691239
Eur J Clin Pharmacol. 1978 Nov 16;14(2):111-6
pubmed: 363431